ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Chirality-Encoded Biomaterials Regulate Local and Systemic Immune Responses in Transplantation.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Biomaterial-based immune modulation offers an opportunity to achieve localized graft acceptance without systemic immunosuppression. Here, we demonstrate that molecular chirality within microporous annealed particle (MAP) hydrogels governs innate and adaptive immune responses in skin transplantation and is associated with modulation of alloimmune outcomes. By engineering injectable MAP scaffolds composed of microgels crosslinked with L- or D-peptides, we show that chirality directs early antigen-presenting cell (APC) activation and trafficking in draining lymph nodes, leading to distinct T cell polarization profiles. A mixed-chirality formulation (R-MAP) composed of L- and D-microgels is associated with reduced APC co-stimulatory signaling (MHC II, CD80, CD86) and preserves graft architecture and tissue integration in syngeneic transplants. In fully allogeneic skin grafts, local mixed-chirality MAP implantation is associated with reduced donor-specific antibody (DSA) formation and attenuated antimaterial and antidonor IgG responses, achieving sustained attenuation of humoral alloimmunity within the experimental conditions studied. These findings establish stereochemical control of biomaterial composition as a design principle for modulating APC-T-B cell crosstalk, linking local material cues to systemic immune outcomes. Mixed-chirality MAP scaffolds thus provide a versatile platform for spatially confined, chirality-guided immunomodulation, with implications for transplantation, regenerative medicine, and biomaterial-driven tolerance strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.